01—Abstract
Summary
Summary of the 10-K filed February 7, 2023. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. reported its sixth consecutive year of annual profitability for 2022, with net income of $182.3 milliona, or $0.56 per diluted share, compared with $231.1 million in 2021.
Total revenues were $1,611.1 millionb, up from $1,434.97 million in 2021, driven by net product revenues of $1,401.2 million (CABOMETYX $1,375.9 million and COMETRIQ $25.3 million). Royalties earned outside the U.S. on cabozantinib sales were $121.4 million in 2022. Operating expenses rose, with research and development at $891.8 million and selling, general and administrative at $459.9 million, reflecting ongoing investment in late-stage trials and the pipeline.
The company held $2.1 billionc in cash, cash equivalents, restricted cash equivalents and investments at year-end, and management states this should support operations for at least 12 months. The company's near-term outlook depends heavily on CABOMETYX. Management projects higher net product revenues in 2023, while also expecting license revenues and collaboration services revenues to decline and research and development and selling, general and administrative expenses to increase.
Key pipeline catalysts include CONTACT-03 and CONTACT-02 primary PFS readouts in 2023, the next OS analysis of COSMIC-313, and the zanzalintinib phase 3 programs STELLAR-303 and STELLAR-304. The COSMIC-313 triplet regimen met its PFS endpoint but did not show a significant OS benefit at a prespecified interim analysis, and the company does not intend to file an sNDA on current data. CONTACT-01 did not meet its primary OS endpoint.
The filing also highlights significant generic-entry risk. Paragraph IV notices from MSN, Teva and Cipla challenge patents covering CABOMETYX. In January 2023, the Delaware District Court ruled in the MSN I case that MSN's ANDA product does not infringe U.S. Patent No. 8,877,776 and set the effective approval date no earlier than August 14, 2026.
The MSN II bench trial is scheduled for October 2023. Investors should weigh strong 2022 growth and profitability against this patent exposure and the company's high spending on discovery and clinical development.
02—Key points
Key Highlights
- Net product revenues rose to $1,401.2 million in 2022 from $1,077.3 million in 2021, with the filing attributing the increase mainly to a 26% rise in CABOMETYX units sold following the first-line RCC approval in combination with OPDIVO.
- Net income was $182.3 million ($0.56 per diluted share) in 2022, down from $231.1 million ($0.72 per diluted share) in 2021; this was the company's sixth year of annual profitability.
- Total revenues were $1,611.1 million, including license revenues of $162.1 million and collaboration services revenues of $47.8 million; royalties on ex-U.S. cabozantinib sales were $121.4 million.
- Research and development expenses increased to $891.8 million from $693.7 million, driven by license and collaboration costs, personnel, and clinical trial spending on zanzalintinib, XB002 and CONTACT-02.
- Cash, cash equivalents, restricted cash equivalents and investments totaled $2.1 billion at December 31, 2022, up from $1.9 billion a year earlier.
- Generic competition risk is material: MSN, Teva and Cipla have filed Paragraph IV ANDA challenges to CABOMETYX, and the company has filed patent infringement suits against MSN and Teva.
- Pipeline setbacks included CONTACT-01 missing its primary OS endpoint and COSMIC-313 not showing a significant OS benefit at interim analysis; the company does not intend to submit an sNDA for the COSMIC-313 regimen based on current data.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2022, Exelixis kept $0.11.
- Revenue$1.61B100.0%
- Cost of revenue−$57.9M3.6%
- Gross profit$1.55B96.4%
- Operating costs−$1.35B83.9%
- Operating income$201.5M12.5%
- Interest, other & tax−$19.2M1.2%
- Net income$182.3M11.3%
Where FY2022 revenue went
$1.61B- R&D: $891.8M, 55% of revenue
- SG&A: $459.9M, 29% of revenue
- Net income: $182.3M, 11% of revenue
- Cost of revenue: $57.9M, 3.6% of revenue
- Interest, other & tax: $19.2M, 1.2% of revenue
Kept 11% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2022filed February 7, 2023Financial Statements
FY2022 against FY2021
| Line item | FY2022FY2021 | Change |
|---|---|---|
| Revenue | $1.61B$1.43B | +12.3% |
| Cost of Revenue | $57.91M$52.87M | +9.5% |
| Gross Profit | $1.55B$1.38B | +12.4% |
| R&D Expenses | $891.81M$693.72M | +28.6% |
| SG&A Expenses | $459.86M$401.71M | +14.5% |
| Operating Expenses | $1.41B$1.15B | +22.8% |
| Operating Income | $201.48M$286.67M | −29.7% |
| Net Income | $182.30M$231.10M | −21.1% |
| EPS (Basic) | $0.57$0.73 | −21.9% |
| EPS (Diluted) | $0.56$0.72 | −22.2% |
| Shares Outstanding (Basic) | 321.53M314.88M | +2.1% |
| Shares Outstanding (Diluted) | 324.56M322.36M | +0.7% |
05—Questions
Frequently Asked Questions
How much of Exelixis's revenue depends on CABOMETYX?
Net product revenues from CABOMETYX were $1,375.9 million in 2022, versus total revenues of $1,611.1 million, and the filing states that sales related to cabozantinib account for the majority of revenues. CABOMETYX is therefore the central driver of the company's financial results.
What is the outlook for 2023 financial results?
Management projects that net product revenues will increase in 2023 as a result of higher market share and selling price. It expects license revenues and collaboration services revenues to decrease, research and development expenses and selling, general and administrative expenses to increase, and an effective tax rate between 20% and 22%.
What is the risk from generic CABOMETYX entry?
MSN, Teva and Cipla have each submitted ANDAs seeking approval for generic CABOMETYX tablets. The company has filed patent suits against MSN and Teva. In January 2023 the Delaware District Court ruled in the MSN I case that MSN's product does not infringe U.S. Patent No. 8,877,776, and set the effective approval date no earlier than August 14, 2026. The MSN II bench trial is scheduled for October 2023. The filing states that generic entry could significantly decrease U.S. CABOMETYX revenues.
What key clinical readouts are expected in 2023?
The filing anticipates primary PFS results from CONTACT-03 in the first half of 2023 and from CONTACT-02 in the second half of 2023. It also expects the next OS analysis of COSMIC-313 in 2023, and it is running phase 3 trials STELLAR-303 and STELLAR-304 for zanzalintinib.
Did the company's profitability decline in 2022?
Net income fell to $182.3 million from $231.1 million in 2021, even as revenue grew to $1,611.1 million. The filing attributes the change to higher operating expenses, including research and development and selling, general and administrative costs, and states the company may not be able to maintain or increase profitability in future periods.
06—Continue